α‐Synuclein Seeds Amplification Assays for Parkinson's Disease and Related Synucleinopathies
- 16 July 2026
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 46 (6) , 1922-1938
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the pathological misfolding and aggregation of α‐synuclein (α‐syn), which leads to dopaminergic neuronal loss and multisystem dysfunction. Conventional clinical diagnosis is often delayed until after substantial neuronal degeneration has occurred. Recent advances in α‐syn seed amplification assays (α‐syn SAAs), including real‐time quaking‐induced conversion (RT‐QuIC) and protein misfolding cyclic amplification (PMCA), have revolutionized PD biomarker research. These assays exploit the prion‐like seeding and propagation properties of pathological α‐syn to amplify trace aggregates in biological samples with exceptional sensitivity and specificity. Here, we summarize the mechanistic principles and biophysical underpinnings of α‐syn SAAs, compare their diagnostic performance across biospecimens such as cerebrospinal fluid, skin, blood, and saliva, and evaluate their potential for differential diagnosis among synucleinopathies. We further discuss the integration of SAAs with other biomarkers including α‐syn oligomer ELISAs, neurofilament light chain assays, and dopaminergic PET/SPECT imaging. Emerging developments, such as same‐day RT‐QuIC, quantitative kinetic readouts, and peripheral blood‐based assays, are accelerating clinical translation. Despite challenges in assay standardization, strain discrimination, and regulatory validation, α‐syn SAAs hold transformative potential for early diagnosis, patient stratification, and monitoring of therapeutic efficacy in PD. Their convergence with artificial intelligence, organoid modeling, and multimodal biomarker frameworks promises to redefine precision medicine in PD and other synucleinopathies.Keywords
Funding Information
- National Medical Research Council
- National Natural Science Foundation of China (82171243)
This publication has 57 references indexed in Scilit:
- A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s diseaseActa Neuropathologica, 2025
- Toward alpha‐synuclein seed amplification assay in clinical practiceAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2025
- Advancing Parkinson’s diagnosis: seed amplification assay for α-synuclein detection in minimally invasive samplesMolecular and Cellular Biochemistry, 2025
- Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevanceAgeing Research Reviews, 2024
- Detection of α‐Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior DisorderMovement Disorders, 2024
- Detecting Misfolded α‐Synuclein in Blood Years before the Diagnosis of Parkinson's DiseaseMovement Disorders, 2024
- A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracyAnnals of Clinical and Translational Neurology, 2020
- Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathiesActa Neuropathologica, 2020
- Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal FluidJAMA Neurology, 2017
- Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathiesAnnals of Clinical and Translational Neurology, 2016